Healthcare provider profile · identity verified

Pauline E Miller, MD

Internal Medicine · LAS VEGAS, NV · NPI 1699731463

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	494	164
Amlodipine Besylate	Amlodipine Besylate	312	108
Losartan Potassium	Losartan Potassium	241	74
Levothyroxine Sodium	Levothyroxine Sodium	205	59
Lisinopril	Lisinopril	190	60
Metformin Hcl	Metformin Hcl	168	58
Rosuvastatin Calcium	Rosuvastatin Calcium	120	41
Albuterol Sulfate Hfa	Albuterol Sulfate	100	27
Gabapentin	Gabapentin	96	37
Allopurinol	Allopurinol	95	30
Fluticasone Propionate	Fluticasone Propionate	88	47
Metoprolol Succinate	Metoprolol Succinate	85	31
Omeprazole	Omeprazole	84	33
Alendronate Sodium	Alendronate Sodium	81	29
Pravastatin Sodium	Pravastatin Sodium	80	23
Simvastatin	Simvastatin	79	23
Pantoprazole Sodium	Pantoprazole Sodium	78	30
Hydrochlorothiazide	Hydrochlorothiazide	72	26
Metformin Hcl Er	Metformin Hcl	71	27
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	64	31
Glipizide Er	Glipizide	63	21
Tamsulosin Hcl	Tamsulosin Hcl	63	24
Sertraline Hcl	Sertraline Hcl	61	17
Metoprolol Tartrate	Metoprolol Tartrate	57	20
Ozempic	Semaglutide	56	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	50	15
Trazodone Hcl	Trazodone Hcl	49	17
Atenolol	Atenolol	47	15
Montelukast Sodium	Montelukast Sodium	47	17
Carvedilol	Carvedilol	45	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	suppressed
Citalopram Hbr	Citalopram Hydrobromide	39	14
Ezetimibe	Ezetimibe	39	15
Jardiance	Empagliflozin	36	suppressed
Clopidogrel	Clopidogrel Bisulfate	32	suppressed
Glipizide	Glipizide	32	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Meloxicam	Meloxicam	29	16
Famotidine	Famotidine	28	14
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Irbesartan	Irbesartan	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	13
Lovastatin	Lovastatin	24	suppressed
Telmisartan	Telmisartan	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Eliquis	Apixaban	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Tradjenta	Linagliptin	20	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Azithromycin	Azithromycin	17	16
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Valsartan	Valsartan	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Furosemide	Furosemide	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error